AIP
ATRA icon

Alexis Investment Partners’s Atara Biotherapeutics ATRA Stock Holding History

Alexis Investment Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$215 – 98
2025
Q3 		$215 Buy
+15
New +$173 ﹤0.01% 94
2025
Q1 		– Sell
-28
Closed -$373 – 48
2024
Q4 		$373 Buy
+28
New +$295 ﹤0.01% 84

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Alexis Investment Partners's ATRA Position: Q4 2025 in Review

Alexis Investment Partners sold out of Atara Biotherapeutics (ATRA) in Q4 2025, closing a stake of 15 shares — an estimated $215 sold.

Alexis Investment Partners first reported a position in ATRA in Q4 2024 and held it in 2 quarters. The position peaked at $373 in Q4 2024. 41 funds tracked by Wall St. Rank hold ATRA as of Q4 2025.

  • Alexis Investment Partners reported no remaining Atara Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Alexis Investment Partners sold 15 Atara Biotherapeutics shares in Q4 2025, an estimated $215.
  • Alexis Investment Partners first reported a position in Atara Biotherapeutics in Q4 2024 and held it in 2 quarters.
  • Alexis Investment Partners's Atara Biotherapeutics position peaked at $373 in Q4 2024.
  • 41 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2025.

Based on Alexis Investment Partners's 13F filing for Q4 2025, filed 29 Jan 2026.